ALK and neoplasm: Patients with mutant ALK VAF ≥20% in their tumor had a 5-year OS of 37.0% versus a 5-year OS of 66.3% in the ALK-WT cohort, and the cohort with VAF 5%-20% demonstrated a similar trend, with a 5-year OS of 40.0%, although a statistically significant difference was not detected in this small patient sample.